Diabetic retinopathy is treated with a combination of eye injections, laser therapy, surgery, and blood sugar management, depending on how far the disease has progressed. In early stages, controlling diabetes itself may be all that’s needed. Once the disease advances to the point where abnormal blood vessels grow or fluid leaks into the central retina, more direct interventions become necessary to preserve vision.
Blood Sugar and Blood Pressure Control
The foundation of every treatment plan starts with managing the underlying diabetes. Keeping your HbA1c below 7% and your blood pressure under 130/80 mmHg slows the progression of retinopathy at every stage. For people with well-controlled diabetes and no signs of retinopathy, some guidelines consider screening intervals as long as every four years safe. Once retinopathy is present, screening tightens to every three to six months depending on severity.
This systemic management matters even after you’ve started receiving eye-specific treatments. Injections and laser therapy address damage that’s already happening, but they work better and last longer when blood sugar and blood pressure aren’t continuously fueling new damage in the background.
Anti-VEGF Injections
Anti-VEGF therapy is the most common treatment for diabetic retinopathy that has progressed to the point of vision threat. These are injections delivered directly into the eye that block a protein called VEGF, which drives the growth of fragile, leaky blood vessels in the retina. By neutralizing this protein, the injections reduce swelling, slow abnormal vessel growth, and help stabilize or improve vision.
The most widely used drugs in this category are aflibercept (Eylea), ranibizumab (Lucentis), and bevacizumab (Avastin). Aflibercept and ranibizumab are both FDA-approved for diabetic retinopathy at any severity level, with or without macular edema. Bevacizumab is technically approved for cancer treatment but is used off-label for eye conditions at a lower cost, and it works through the same basic mechanism. A newer option, faricimab (Vabysmo), approved in 2022, targets both VEGF and a second protein involved in blood vessel instability. In clinical trials, faricimab allowed some patients to extend their treatment intervals to every 16 weeks while maintaining visual benefit.
The injection itself takes only a few minutes. Your eye is numbed with drops beforehand, and most people describe the sensation as pressure rather than sharp pain. Treatment typically begins with monthly injections during a loading phase until your condition stabilizes. After that, your doctor will either extend the interval gradually (a “treat and extend” approach) or schedule regular check-ups and inject only when signs of worsening appear. From a drug-level standpoint, monthly injections are needed to maintain continuous suppression of VEGF, but many patients do well with longer intervals once the disease is under control. The ongoing nature of these injections is one of the biggest challenges of treatment, as some patients need them for years.
Laser Therapy
Laser treatment takes two distinct forms depending on the problem being addressed.
For proliferative diabetic retinopathy, where dangerous new blood vessels have started growing, the standard approach is panretinal photocoagulation (PRP), also called scatter laser. This involves applying hundreds to thousands of tiny laser burns across the peripheral retina. It works by deliberately destroying a fraction of the light-sensing cells in the outer edges of the retina, which reduces the retina’s overall oxygen demand. With less oxygen being consumed, the signals that trigger abnormal blood vessel growth quiet down. You do lose some peripheral and night vision as a trade-off, but the treatment is effective at preventing the severe complications that cause blindness.
For diabetic macular edema, where fluid leaks into the central retina and blurs your vision, focal or grid laser is sometimes used. Focal laser targets specific points of leakage, while grid laser covers a broader area of diffuse swelling. These treatments are applied only to a small area near the center of the retina, unlike the widespread burns of scatter laser. Focal laser was once the primary treatment for macular edema but has largely been supplemented or replaced by anti-VEGF injections, which tend to produce better visual outcomes. Laser is still used in combination with injections or when injections alone aren’t enough.
Steroid Implants
When macular edema doesn’t respond well to anti-VEGF injections, corticosteroid implants offer an alternative. These work by reducing inflammation, tightening the junctions between retinal blood vessel cells, and suppressing both inflammatory molecules and VEGF simultaneously.
Two implants are commonly used. Ozurdex is a tiny biodegradable implant injected into the eye that releases medication over several months before dissolving on its own. Iluvien is a longer-lasting implant approved in the U.S. specifically for patients with chronic macular edema who’ve already been treated with corticosteroids without experiencing a problematic rise in eye pressure. The main risk with steroid implants is that they can increase pressure inside the eye and accelerate cataract formation, so they’re generally reserved for patients who haven’t responded to first-line treatments or who can’t maintain the frequent injection schedule that anti-VEGF therapy requires.
Vitrectomy Surgery
Surgery becomes necessary when diabetic retinopathy causes structural problems inside the eye that injections and laser can’t fix. The primary procedure is vitrectomy, in which a surgeon removes the gel-like substance (the vitreous) filling the center of the eye, along with any blood, scar tissue, or membranes pulling on the retina.
The most common reason for vitrectomy is a vitreous hemorrhage that won’t clear on its own. When abnormal blood vessels bleed into the vitreous, your vision can become severely clouded. Doctors typically wait about four weeks to see if the blood reabsorbs naturally. If it doesn’t, surgery clears the obstruction and restores sight. The second major indication is tractional retinal detachment, where scar tissue from proliferative retinopathy contracts and physically pulls the retina away from the back of the eye. If the central retina (the fovea) is involved, surgery needs to happen as soon as possible to prevent permanent vision loss. When a tractional detachment combines with a tear-related detachment, the situation can deteriorate rapidly, making urgent intervention critical.
Vitrectomy is also performed for macular edema that’s being caused by physical traction on the retina from scar tissue. In these cases, removing the vitreous and peeling away the membrane can improve oxygen and nutrient flow to the retina in ways that injections alone cannot. The surgery itself involves small-gauge instruments inserted through tiny incisions in the white of the eye, and it may include laser treatment, dye-assisted membrane removal, and the placement of a gas or silicone oil bubble to hold the retina in place during healing. Recovery varies, but many patients need to maintain a specific head position for days to weeks afterward if a gas bubble is used.
How Treatments Work Together
In practice, most people with advanced diabetic retinopathy receive a combination of these treatments rather than just one. A patient with proliferative retinopathy might get anti-VEGF injections to quickly shrink new blood vessels, followed by scatter laser to provide longer-lasting protection. Someone with macular edema might start with monthly injections, add focal laser if the response plateaus, and switch to a steroid implant if inflammation persists. If a vitreous hemorrhage develops, vitrectomy clears the way, and laser or injections follow to address the underlying disease.
The earlier retinopathy is caught, the less aggressive the treatment needs to be. People with diabetes who have no signs of retinopathy can safely screen every one to two years. Once retinopathy appears, that interval shortens to annually or every three to six months based on severity. Catching the disease before it reaches the proliferative stage or before macular edema develops gives you the widest range of treatment options and the best chance of keeping your vision stable long-term.